Antonio Gotto, M.D., D. Phil.
|B.A.||Vanderbilt University (Biochemistry)|
|D. Phil.||University of Oxford (Biochemistry)|
|M.D.||Vanderbilt University School of Medicine|
Postdoctoral Research Scholar, American Cancer Society
Intern and Assistant Resident, Massachusettes General Hospital (Medicine)
Dr. Antonio M. Gotto is the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College in New York, New York, where he is also Professor of Medicine. In addition, Dr. Gotto is Provost for Medical Affairs of Cornell University. He joined The Methodist Hospital Research Institute in 2011. Previously, at Baylor College of Medicine in Houston, Texas, he was the Bob and Vivian Smith Professor and Chairman of the Department of Medicine, Scientific Director of the DeBakey Heart Center, and the JS Abercrombie Chair for Atherosclerosis and Lipoprotein Research. He also served as Chief of the Internal Medicine Service at The Methodist Hospital in Houston. Dr. Gotto's postgraduate work included doctoral studies at Oxford University in England as a Rhodes Scholar, and residency training at the Massachusetts General Hospital in Boston, Massachusetts.
As a lifelong supporter of educational efforts aimed at cardiovascular risk reduction, Dr. Gotto has been National President of the American Heart Association and President of the International Atherosclerosis Society. He is a member of the Institute of Medicine and the American Academy of Arts and Sciences and a recipient of many honors, including the Gold Heart Award from the American Heart Association, the 2000 Distinguished Alumnus award from Vanderbilt University and the Vanderbilt University School of Medicine, honorary doctoral degrees from the University of Bologna and Abilene Christian University, honorary professorships from the University of Buenos Aires and Francisco Marroquin University (Guatemala), and the Order of the Lion from the Republic of Finland. Dr. Gotto was the 2004 recipient of the International Okamoto Award from the Japan Vascular Disease Research Foundation. In 2004 Dr. Gotto was also named Honorary Member of the Society for Progress in Internal Medicine (Ludwig Heilmeyer Society) in Germany. In 2010, he received the Maurice R. Greenberg Distinguished Service Award, the highest honor bestowed by New York-Presbyterian/Weill Cornell on members of the medical staff.
Dr. Gotto speaks nationally and internationally on cardiovascular disease and has contributed more than 500 scholarly articles and books to the medical literature. In addition, he is coauthor of a series of books that explain the origins and treatment of cardiovascular disease to the general public.
In the field of atherosclerosis, his basic science research interests include clinical disorders of lipid transport and the structure, metabolism, and function of lipoproteins and apolipoproteins. He and his associates were the first to achieve complete synthesis of a plasma apolipoprotein (apo C-I); they also determined the complete cDNA and amino acid sequence of apo B-100, one of the largest proteins ever sequenced and a key protein in atherosclerosis. In addition, Dr. Gotto has played a leading role in several landmark clinical trials demonstrating that cholesterol-lowering drug treatment can reduce the risk of heart disease.
Lipoproteins and apolipoproteins, atherosclerosis, lipid metabolism, statins
Grattoni Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16;363(25):2406-15.
Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFayden JG, Glynn RJ, Kastelein JJ; JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376(9738):333-9.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley DM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375(9716):735-42.
Chen SN, Cilingiroglu M, Todd J, Lombardi R, Willerson JT, Gotto AM Jr, Ballantyne CM, Marian AJ. Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Med Genet. 2009;10:111.
Nakaya H, Summers BD, Nicholson AC, Gotto AM Jr, Hajjar DP, Han J. Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. Am J Pathol. 2009;174(6):2007-14.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670): 1175-82.
Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Mafadyen JG, Nordestgaard BG, Shepard J, Willerson JT, Ridker PM. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. N Engl J Med. 2009;360(18):1851-61.
Lamon BD, Summers BD, Gotto AM Jr, Hajjar DP. Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1induction in human vascular smooth muscle cells. Eur J Pharmacol. 2009;606(1-3):72-76.
Ridker PM, Danileson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207.
Zhou X, He W, Huang Z, Gotto AM Jr, Hajjar DP, Han J. Genetic deletion of low density lipoprotein receptor impairs sterol-induced mouse macrophage ABCA1 expression. A new SREBP1-dependent mechanism. J Biol Chem. 2008;283(4):2129-38.
Barter P, Gotto AM Jr, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301-10.
Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2006;48(9):1793-9.